Ai Virtual Agent Selection, Implementation and Support Keys to Success
Improving Population Health via Non-traditional Partnerships
Efficient Data Management in the Healthcare Space
Transform Healthcare with a Passion for Innovation
Significant technological change often means a cultural shift for...
NovletMattis, Chief Information Officer, Orlando Health
Disrupting the CIO Comfort Zone to Innovate and Transform How...
Wes Williams, VP & CIO, Mental Health Center Of Denver
Bringing the Worlds of Technology and Health Closer to Each Other
Kristin Myers, Chief Information Officer, Mount Sinai Health System
The Biopsychosocial Model: The Future of Remote Patient Monitoring
Heather Comerci Reyes, Md, Me; Michael Hasselberg, Phd, Chief Digital Health Officer, University Of Rochester Medical Center
Thank you for Subscribing to CIO Applications Weekly Brief
The discovery of drugs is a long and often an arduous process with the typical marketing time of 14 years, and the cost of the drug is billions. AI offers a way of accelerating development and reducing costs. The development of drugs depends in part on biomedical data. Such data are always highly complex, and the interactions between hundreds of biological entities are also complex.
Today, research at the cutting edge of cancer research involves billions of permutations which could occur. Some cancers grow every two seconds and never die; some grow 16 times every second and die every five days, and some grow every five days, never die. Each calls for a different approach, therapy, or management method.
Science and technology strive to understand the discovery of drugs. It is necessary to know how it works, how to control it, and how to avoid further imbalance in a patient.
Open source software is not available for the required analytical types, and proprietary algorithms are required. BioSymetrics uses AI to process raw phenotypes, imaging, drugs, and genomic data sets and enables researchers to integrate rapid analytics and machine learning capabilities into existing business processes to improve care, improve discoveries, gain business insight, and enable fast data-driven decision-making.
Cambridge Cancer Genomics, a U.S. research foundation, predicts cancer progression from tumor DNA in blood samples using AI technology. The technology allows researchers to determine earlier treatment response and relapse and to use Bayesian adaptive clinical trial design to increase the success of late-stage studies.
CytoReason, an Israel-based bioinformatics company, uses AI to organize and standardize immune-related gene, protein, cell, and microbiome data into a single cell-level, machine-readable immune system view. Company researchers can gain new insights into disease mechanisms, clinical markers, and drug discovery and validation.
Standigm uses state-of-the-art AI technologies to detect and develop drugs, understand how drug compounds interact with people in the real world. The current focus of the company is to forecast new indications for existing medicines. In EU, there is a legislative proposal for new regulations on medical devices, which offers software for medical devices with the purpose of prediction and prognosis.
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info
Featured Vendors
-
Jason Vogel, Senior Director of Product Strategy & Development, Silver Wealth Technologies
James Brown, CEO, Smart Communications
Deepak Dube, Founder and CEO, Datanomers
Tory Hazard, CEO, Institutional Cash Distributors
Jean Jacques Borno, CFP®, Founder & CEO, 1787fp
-
Andrew Rudd, CEO, Advisor Software
Douglas Jones, Vice President Operations, NETSOL Technologies
Matt McCormick, CEO, AddOn Networks
Jeff Peters, President, and Co-Founder, Focalized Networks
Tom Jordan, VP, Financial Software Solutions, Digital Check Corp
Tracey Dunlap, Chief Experience Officer, Zenmonics